HBV antisense inhibitors
US8598334B2 · kind B2 · utility
12Cited by
2References
35Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 15, 2010 |
| Grant date | Dec 3, 2013 |
| Priority date | — |
| Expiry date | Oct 15, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antisense oligomers useful for modulating hepatitis B virus infections, and for the treatment of hepatitis B virus (HBV) and hepatitis B virus-related conditions in animals including humans. More particularly, antisense oligomers with modified nucleotides for treatment of HBV in animals, more particularly antisense oligomers comprising 2′O-4′C-methylene-bridged sugars, or nucleotides with other 2′O-4′C bridged sugars, also known as locked nucleic acids (LNA), for treatment of HBV in animals, and more particularly for treatment of HBV in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.